Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

CMS To Give More Specifics For Use Of Coverage With Evidence Development

Executive Summary

The Centers for Medicare & Medicaid Services will offer greater clarity on when it will require data collection as a condition of Medicare Part B coverage in a second draft of its guidance on the topic

You may also be interested in...



Medicare Proposes To Cover J&J’s Natrecor For Labeled Indication Only

The Centers for Medicare & Medicaid Services is proposing to restrict Medicare coverage of Johnson & Johnson/Scios' Natrecor to its labeled indication for acutely decompensated heart failure, rather than provide wider coverage for the drug under a "coverage with evidence development" program

CMS To Use Coverage With Evidence Development When Rx Benefit Is Likely

The Centers for Medicare & Medicaid Services will use coverage with evidence development only when an agent is highly likely to show benefit in a broader patient population than its labeled indication, CMS Senior Advisor Peter Bach said Dec. 5

Medicare Proposes To Cover J&J’s Natrecor For Labeled Indication Only

The Centers for Medicare & Medicaid Services is proposing to restrict Medicare coverage of Johnson & Johnson/Scios' Natrecor to its labeled indication for acutely decompensated heart failure, rather than provide wider coverage for the drug under a "coverage with evidence development" program

Related Content

Topics

UsernamePublicRestriction

Register

PS046112

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel